Australia
# |
Name |
EBIT |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 3.79 B
|
June 30, 2024 | USD 173.13 | 0.11% |
|
Australia |
|
2 |
USD 36.76 M
|
June 30, 2024 | USD 7.32 | 6.16% |
|
Australia |
|
3 |
USD 27.49 M
|
June 30, 2024 | USD 2.14 | 0.82% |
|
Australia |
|
4 |
USD 11.05 M
|
Dec. 31, 2023 | USD 15.47 | 4.25% |
|
Australia |
|
5 |
USD 9.40 M
|
June 30, 2024 | USD 2.01 | -0.68% |
|
Australia |
|
6 |
USD 1.62 M
|
June 30, 2024 | USD 1.33 | 6.17% |
|
Australia |
|
7 |
USD -4.62 M
|
June 30, 2024 | USD 2.00 | 1.52% |
|
Australia |
|
8 |
USD -13.15 M
|
June 30, 2024 | USD 3.31 | -4.06% |
|
Australia |
|
9 |
USD -15.13 M
|
June 30, 2024 | USD 3.66 | 3.57% |
|
Australia |
|
10 |
USD -17.72 M
|
June 30, 2024 | USD 0.62 | -2.68% |
|
Australia |
|
11 |
USD -19.09 M
|
June 30, 2024 | USD 1.53 | 1.32% |
|
Australia |
|
12 |
USD -26.13 M
|
June 30, 2024 | USD 0.74 | -1.40% |
|
Australia |
|
13 |
USD -29.87 M
|
June 30, 2024 | USD 2.37 | 1.84% |
|
Australia |
|
14 |
USD -31.04 M
|
June 30, 2024 | USD 1.93 | -0.52% |
|
Australia |
|
15 |
USD -47.46 M
|
Dec. 31, 2023 | USD 5.88 | 0.14% |
|
Australia |
|
16 |
USD -57.97 M
|
June 30, 2024 | USD 1.58 | -2.06% |
|
Australia |
|
17 |
USD -200.12 M
|
June 30, 2024 | USD 3.82 | 6.70% |
|
Australia |
The Biotechnology company in Australia with the highest EBIT is CSL Limited (ASX: CSL.AX) at USD 3.79 B.
The Biotechnology company in Australia with the lowest EBIT is Opthea Limited (NasdaqGS: OPT) at USD -200.12 M.
The top 10 Biotechnology companies in Australia by EBIT are CSL Limited, Clinuvel Pharmaceuticals Limited, Australian Clinical Labs Limited, Telix Pharmaceuticals Limited, Nanosonics Limited, PolyNovo Limited, Immuron Limited, Alterity Therapeutics Limited, Silex Systems Limited and Trajan Group Holdings Limited.
The bottom 10 Biotechnology companies in Australia by EBIT are Opthea Limited, Mesoblast Limited, Anteris Technologies Ltd, Immutep Limited, Clarity Pharmaceuticals Ltd, PYC Therapeutics Limited, Kazia Therapeutics Limited, Trajan Group Holdings Limited, Silex Systems Limited and Alterity Therapeutics Limited.